araag2/HINT huggingface dataset:
Clinical trial NCT00543725 (phase 3, status: completed)
Conditions: hiv infections, hiv-1
ICD codes: Z21, B20, Z71.7, O98.72, Z21, O98.73, R75, Z11.4
Drugs: tmc278, efavirenz
SMILES: CC1=CC(\C=C\C#N)=CC(C)=C1NC1=CC=NC(NC2=CC=C(C=C2)C#N)=N1, [H][C@@](C)(CN1C=NC2=C(N)N=CN=C12)OCP(=O)(OCOC(=O)OC(C)C)OCOC(=O)OC(C)C
Eligibility criteria:

        Inclusion Criteria:

          -  Patient with documented HIV-1 infection

          -  Patient has never been treated with a therapeutic HIV vaccine or an ARV drug prior to
             screening

          -  Patient's HIV-1 plasma viral load at screening is > 5,000 HIV-1 RNA copies/mL (assayed
             by RNA PCR standard specimen procedure)

          -  Patient's virus is sensitive to the 2 nucleoside/nucleotide reverse transcriptase
             inhibitors chosen for treatment

          -  Patient agrees not to start ART before the baseline visit

          -  Patient is HLA-B*5701 negative in case abacavir is included in the patient's treatment
             regimen.

        Exclusion Criteria:

          -  Previous use of ANY ARV drug for ANY length of time

          -  Any documented evidence of NNRTI resistance associated mutations in patient's HIV

          -  Category C AIDS defining illness, except, Stable Kaposi Sarcoma Wasting syndrome if
             not progressive

          -  Pneumocystis carinii pneumonia (PCP) that is considered not cured

          -  Active TB

          -  Allergy or hypersensitivity to study or background ARTs

          -  Specific grade 3 or 4 toxicity

          -  Kidney impairment: calculated creatinine clearance <50 ml/min
Clinical trial NCT00515320 (phase 3, status: completed)
Conditions: autistic disorder
ICD codes: F84.0
Drugs: fluoxetine, placebo
SMILES: CNCCC(OC1=CC=C(C=C1)C(F)(F)F)C1=CC=CC=C1, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Meets DSM-IV criteria for autistic disorder, .

          -  CYBOCS-PDD score of at least 10 at screening.

        Exclusion Criteria:

          -  Diagnosis of Asperger Syndrome or Pervasive Developmental Disorder Not Otherwise
             Specified, Rett Syndrome, Childhood Disintegrative Disorder.

          -  Patients planning to commence cognitive behaviour therapy during the period of the
             study or those who have begun cognitive behaviour therapy within 8 weeks prior to
             enrolment.

          -  Patients who are currently taking fluoxetine or who have previously taken it are not
             eligible for the study.

        Other protocol-defined Inclusion/Exclusion criteria may apply.
Clinical trial NCT00330473 (phase 3, status: completed)
Conditions: diabetes mellitus, type 2
ICD codes: E11.65, E11.9, E11.21, E11.36, E11.41, E11.42, E11.44
Drugs: human insulin inhalation powder, insulin
SMILES: [Na+].[Na+].[O-]P([O-])(F)=O, [Na+].[Na+].[O-]P([O-])(F)=O
Eligibility criteria:

        Inclusion Criteria:

          -  Type 2 Diabetes

          -  Insulin-naive

          -  Non-smoker

        Exclusion Criteria:

          -  Significant pulmonary, hepatic or renal disease

          -  severe congestive heart failure

          -  active malignancy or malignancy within the last 5 years

          -  systemic glucocorticoid therapy
Clinical trial NCT00160615 (phase 3, status: completed)
Conditions: epilepsy, partial
ICD codes: G40.111, G40.119, G40.211, G40.219, G40.101, G40.109, G40.201
Drugs: levetiracetam
SMILES: CC(C)CC1=CC=C(C=C1)C(C)C(O)=O
Eligibility criteria:

        Inclusion Criteria:

          -  Patients who completed the evaluation period (Week 16) of N165 Clinical Trial of L059

          -  Patients/the parent or guardian wish to continue treatment with L059 and to enter N165
             Follow-up Study, and also the investigator admit the necessity of the repeated intake
             of the investigational drug for the patients.

        Exclusion Criteria:

          -  Patients who had not participate in N165 Clinical Trial of L059.

          -  Patients who had participated in N165 Clinical Trial of L059 with no intention of
             entering the follow-up study taking the same medication.

          -  Patients had not been in compliance with requirements of Protocol for N165 Clinical
             Trial of L059 in the course of the study.
Clinical trial NCT01602003 (phase 3, status: completed)
Conditions: type 2 diabetes mellitus
ICD codes: E11.65, E11.9, E11.21, E11.36, E11.41, E11.42, E11.44
Drugs: lc15-0444 25mg bid, lc15-0444 50mg qd, sitagliptin 100mg qd
SMILES: N[C@H](CN1CC(F)(F)CCC1=O)CC(=O)N1CCC2=C(C1)N=C(N=C2C(F)(F)F)C(F)(F)F, N[C@H](CN1CC(F)(F)CCC1=O)CC(=O)N1CCC2=C(C1)N=C(N=C2C(F)(F)F)C(F)(F)F, N[C@@H](CC(=O)N1CCN2C(C1)=NN=C2C(F)(F)F)CC1=CC(F)=C(F)C=C1F
Eligibility criteria:

        Inclusion Criteria:

          1. Patients with Type 2 Diabetes Mellitus

          2. Adults between 18 and 75 years of age

          3. Patients with HbA1c between 7% and 11%

          4. Patients treated with metformin monotherapy for at least 12 weeks and treated with
             1000 mg/day or higher dose of metformin for at least 4 weeks right before screening

          5. Patients who signed on the consent form after informed on the object, method, and
             risks of the clinical study

        Exclusion Criteria:

          1. Patients with type 1 diabetes mellitus, gestational diabetes, or secondary diabetes

          2. Patients who were taking or needed to take any drugs which may affect the control of
             blood glucose significantly (ex. glucocorticoids)

          3. Patients who had experienced myocardial infarction, unstable angina or prior history
             of coronary artery bypass surgery within 6 months prior to screening, or patients with
             arrhythmia requiring treatment

          4. Patients with NYHA class II-IV congestive heart failure

          5. Patients with history of hepatic cirrhosis

          6. Patients with renal failure or whose creatinine clearance was less than 60 ml/min

          7. Patients with dysfunctional thyroid gland (with abnormal level of TSH)

          8. Patients with ALT, AST or CPK exceeding 2.5 times of the upper limit of the normal
             range

          9. Patients with BMI below 20 kg/m2 or exceeding 40 kg/m2

         10. Patients with history of asthma or major skin allergy

         11. Patients taking thyroid hormone, warfarin, dicoumarin or digoxin.

         12. Patients with history of hypersensitivity to metformin or biguanides.

         13. Patients with history of hypersensitivity to thiazolidinediones

         14. Patients who took sodium channel blockers in the last 6 weeks prior to Visit 1.

         15. Patients who were treated with insulin or glucagon-like peptide-1 (GLP-1) analogue or
             who took thiazolidinediones (Glitazone) in the last 6 months prior to Visit 1.

         16. Patients with other reasons who the investigator decided not to be eligible for the
             study
Clinical trial NCT01572792 (phase 3, status: completed)
Conditions: chronic obstructive pulmonary disease
ICD codes: J44.9, J44.1, J44.0
Drugs: aclidinium bromide/formoterol fixed-dose combination (fdc), aclidinium bromide/formoterol fixed-dose combination (fdc), aclidinium bromide, formoterol fumarate, placebo
SMILES: OC(C(=O)O[C@H]1C[N+]2(CCCOC3=CC=CC=C3)CCC1CC2)(C1=CC=CS1)C1=CC=CS1, OC(C(=O)O[C@H]1C[N+]2(CCCOC3=CC=CC=C3)CCC1CC2)(C1=CC=CS1)C1=CC=CS1, OC(C(=O)O[C@H]1C[N+]2(CCCOC3=CC=CC=C3)CCC1CC2)(C1=CC=CS1)C1=CC=CS1, COC1=CC=C(CC(C)NCC(O)C2=CC(NC=O)=C(O)C=C2)C=C1, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Completion of the treatment phase of the lead-in study, LAC-MD-31

          -  Written informed consent obtained from the patient before the initiation of any study
             specific procedures

          -  No medical contraindication as judged by the PI

          -  Compliance with LAC-MD-31 study procedures and IP dosing.

        Exclusion Criteria:

          -  No specific exclusion criteria
Clinical trial NCT00372333 (phase 3, status: completed)
Conditions: joint pain, musculoskeletal pain, stiffness, soft tissue inflammation in designated target area(s)
ICD codes: M25.50, M25.59, M25.541, M25.542, M25.549, M25.571, M25.572
Drugs: idea-033
SMILES: CC(C(O)=O)C1=CC(=CC=C1)C(=O)C1=CC=CC=C1
Eligibility criteria:

        Inclusion Criteria:

          -  at least 18 years or older

          -  agree to refrain from chronic usage of NSAIDs or any other analgesics or
             anti-inflammatory drugs other than those provided during the course of the study or
             documented sporadic concomitant analgesics

          -  joint pain, musculoskeletal pain, stiffness, or soft tissue inflammation in designated
             target area(s) that are appropriate for self-treatment with a topical analgesic or
             where availability of a second person can be guaranteed in case self-treatment is not
             possible

          -  healthy skin in the target area(s)

        Exclusion Criteria:

          -  known hypersensitivity to IDEA-033 or other NSAIDs

          -  history of coagulation disorders

          -  history of peptic ulcers or gastric intolerance with NSAIDs

          -  urinary tract infection

          -  clinically significant renal, hepatic, or gastric disease

          -  acute or chronic coexisting illness qualifying for exclusion according to clinical
             judgement of the investigator

          -  clinical laboratory values outside normal range deemed clinically significant by the
             investigator

          -  Narcotics-containing products within 7 days of administering IMP

          -  Malignancy within the past 2 years
Clinical trial NCT00271817 (phase 3, status: completed)
Conditions: hypercholesterolemia
ICD codes: E78.01, E78.00, Z83.42
Drugs: comparator: ezetimibe/simvastatin + niacin (er), comparator: placebo to ezetimibe/simvastatin, comparator: niacin (er) tablet, comparator: ezetimibe (+) simvastatin, comparator: placebo to niacin (er), comparator: ezetimibe/simvastatin and niacin (er), comparator: ezetimibe and simvastatin, comparator: placebo to niacin (er)
SMILES: OC(=O)C1=CN=CC=C1, O[C@@H](CC[C@@H]1[C@H](N(C1=O)C1=CC=C(F)C=C1)C1=CC=C(O)C=C1)C1=CC=C(F)C=C1, OC(=O)C1=CN=CC=C1, CC(C)C1=C(C(=O)NC2=CC=CC=C2)C(=C(N1CC[C@@H](O)C[C@@H](O)CC(O)=O)C1=CC=C(F)C=C1)C1=CC=CC=C1, OC(=O)C1=CN=CC=C1, OC(=O)C1=CN=CC=C1, O[C@@H](CC[C@@H]1[C@H](N(C1=O)C1=CC=C(F)C=C1)C1=CC=C(O)C=C1)C1=CC=C(F)C=C1, OC(=O)C1=CN=CC=C1
Eligibility criteria:

        Inclusion Criteria:

          -  Patient with LDL-C of 130 through 190 mg/dL and Triglycerides less than or equal to
             500 mg/dL

          -  Patient willing to be on a low-cholesterol diet

        Exclusion Criteria:

          -  Pregnant or lactating women or intending to become pregnant

          -  Patient with sensitivity or intolerance to ezetimibe, simvastatin, or
             ezetimibe/simvastatin combination tablet

          -  Patient with sensitivity or intolerance ro niacin, any component or niacin extended
             release or aspirin

          -  Patient for whom discontinuation of existing lipid-lowering therapy treatment poses an
             unacceptable risk
Clinical trial NCT00623103 (phase 3, status: completed)
Conditions: parkinson's disease dementia
ICD codes: G20
Drugs: rivastigmine capsule, rivastigmine transdermal patch
SMILES: CCN(C)C(=O)OC1=CC=CC(=C1)[C@H](C)N(C)C, CCN(C)C(=O)OC1=CC=CC(=C1)[C@H](C)N(C)C
Eligibility criteria:

        Inclusion Criteria:

          -  Diagnosis of idiopathic Parkinson's disease, according to the UK Parkinson's disease
             Society Brain Bank criteria

          -  Diagnosis of Parkinson's disease dementia according to Diagnostic and Statistical
             Manual of Mental Disorders, Fourth Edition (DSM-IV) criteria, with onset of symptoms
             of dementia at least 2 years following the first diagnosis of idiopathic Parkinson's
             disease

          -  Mini Mental State Examination score of ≥10 and ≤ 26 (at Screening Visit only)

        Exclusion Criteria:

          -  An advanced, severe, or unstable disease of any type that may interfere with the
             primary and secondary variable evaluations

          -  A score of 5 (wheelchair bound or bedridden) in the "on"-state on the Modified Hoehn
             and Yahr Staging (UPDRS Part V)

          -  A current diagnosis of any primary neurodegenerative disorder other than idiopathic PD

          -  A current diagnosis of any treatable dementia (hypothyroidism, syphilis, vitamin B12
             or folate deficiency) that is verified by the investigator to be the cause of
             dementia.

          -  A current diagnosis of probably vascular dementia according to the National Institute
             of Neurological Disorders and Stroke and the Association International pour la
             Recherche et l'Enseignement en Neurosciences (NINDS-AIREN) criteria

          -  A current diagnosis of a major depressive episode according to DSM-IV criteria

          -  A history of stereotaxic brain surgery for Parkinson's disease

          -  A known exaggerated pharmacological sensitivity or hypersensitivity to drugs similar
             to rivastigmine or to other cholinergic compounds

        Other protocol-defined inclusion/exclusion criteria may apply.
Clinical trial NCT00143403 (phase 3, status: completed)
Conditions: colorectal neoplasms, liver neoplasms
ICD codes: C05.2, C10.0, C16.0, C16.4, C17.0, C17.1, C17.2, D13.4, Z85.05, C22.8, C78.7, C22.9, D37.6
Drugs: irinotecan + 5 fu + folinic acid, folinic acid + 5 fu
SMILES: CC[C@@]1(O)C(=O)OCC2=C1C=C1N(CC3=CC4=CC=CC=C4N=C13)C2=O
Eligibility criteria:

        Inclusion Criteria:

          -  Histologically proven adenocarcinoma of the colon or rectum with complete resection of
             primary tumour.

          -  Complete surgical resection (R0) of the liver metastasis(es) within a minimum of 3
             weeks, and a maximum of 8 weeks prior to the first study treatment infusion.

          -  Exclusively hepatic metastasis (es) : absence of bone, lung and brain metastases.

        Exclusion Criteria:

          -  Prior hepatic radiation or resection.

          -  Prior radiofrequency ablation or cryoablation Incomplete surgical resection of liver
             metastasis (es).

          -  Prior chemotherapy for metastatic disease.
Clinical trial NCT00174577 (phase 3, status: unknown status)
Conditions: major depression
ICD codes: F32.A, F53.0, P91.4, Z13.31, Z13.32
Drugs: risperidone
SMILES: OCCOCCN1CCN(CC1)C1=NC2=CC=CC=C2SC2=CC=CC=C12
Eligibility criteria:

        Inclusion Criteria:

          -  patients with major depression or partially remitted depression

          -  currently receiving an adequate trial of an antidepressant

        Exclusion Criteria:

          -  diagnosis of bipolar I or bipolar II disorder

          -  psychotic features

          -  substance dependence or abuse in the past three months
Clinical trial NCT00265330 (phase 3, status: completed)
Conditions: bipolar disorder
ICD codes: F31.81, F31.89, F31.9, F25.0, F31.0, F31.31, F31.32
Drugs: ziprasidone oral capsules
SMILES: ClC1=C(CCN2CCN(CC2)C2=NSC3=CC=CC=C23)C=C2CC(=O)NC2=C1
Eligibility criteria:

        Inclusion Criteria:

          -  Participation in double-blind treatment study A1281132, meeting specific criteria of
             duration and safety

        Exclusion Criteria:

          -  Imminent risk of suicide or homicide, as judged by the site investigator;serious
             adverse event related to study medication in study A1281132; significant prolongation
             of QT interval in study A1281132.
Clinical trial NCT00099268 (phase 3, status: completed)
Conditions: parkinson's disease
ICD codes: G20
Drugs: carbidopa/levodopa/entacapone, immediate release carbidopa/levodopa
SMILES: C[C@@](CC1=CC(O)=C(O)C=C1)(NN)C(O)=O, C[C@@](CC1=CC(O)=C(O)C=C1)(NN)C(O)=O
Eligibility criteria:

        Inclusion Criteria:

          -  Clinical diagnosis of idiopathic Parkinson's disease

          -  Diagnosis of Parkinson's disease for no more than 5 years

        Exclusion Criteria:

          -  History, signs, or symptoms of atypical or secondary parkinsonism

          -  Presence at baseline of drug-related wearing-off symptoms, dyskinesia or other motor
             complications

          -  Levodopa exposure of more than 30 days or anytime within 8 weeks prior to visit 1

        Other inclusion/exclusion criteria applied to this study.
Clinical trial NCT00454207 (phase 3, status: completed)
Conditions: pulmonary hypertension
ICD codes: I27.0, I27.20, I27.21, I27.24, I27.29, P29.30, I27.22
Drugs: sildenafil citrate (uk-92,480)
SMILES: CCCC1=NN(C)C2=C1NC(=NC2=O)C1=C(OCC)C=CC(=C1)S(=O)(=O)N1CCN(C)CC1
Eligibility criteria:

        Inclusion Criteria:

          -  Subjects aged 16 and over, and classified as having pulmonary arterial hypertension

          -  Subjects who meet the following conditions on right heart catheterization at screening
             or baseline: mean pulmonary arterial pressure of ≥ 25mmHg and pulmonary capillary
             wedge pressure of ≤ 15mmHg at rest

          -  Subjects whose baseline 6-Minute Walk test distance is >100 m and <450 m

        Exclusion Criteria:

          -  Significant Hepatic and/or renal disorder

          -  Subjects with known hereditary degenerative retinal disorders (such as retinitis
             pigmentosa) or history of non-arteritic ischemic optic neuropathy (NAION)

          -  Subjects who are currently receiving nitrates or nitric oxide donors in any form,
             ritonavir, ketoconazole and itraconazole
Clinical trial NCT01143077 (phase 3, status: completed)
Conditions: schizophrenia, schizoaffective disorder
ICD codes: F20.0, F20.1, F20.2, F20.3, F20.5, F20.89, F20.9, F25.9, F25.0, F25.1, F25.8
Drugs: lurasidone hcl
SMILES: CO[C@H]1\C=C\O[C@@]2(C)OC3=C(C2=O)C2=C(O)C(\C=N\N4CCN(C)CC4)=C(NC(=O)\C(C)=C/C=C/[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@@H]1C)C(O)=C2C(O)=C3C
Eligibility criteria:

        Inclusion Criteria:

          -  Subject ≥ 18 years of age.

          -  Subject meets DSM-IV criteria for a primary diagnosis of schizophrenia or
             schizoaffective disorder.

          -  Subject must be judged by the investigator to be an appropriate candidate for
             switching current antipsychotic medication due to insufficient efficacy and/or safety
             or tolerability concerns.

        Exclusion Criteria:

          -  Presence of an Axis I or Axis II disorder other than schizophrenia or schizoaffective
             disorder that is the primary focus of treatment prior to screening.

          -  Subject has experienced persistent lack of improvement in psychotic symptoms despite
             adequate trials (at least 6 weeks at standard doses), of two or more antipsychotic
             agents in the 12 months prior to screening.

          -  Subject is considered by the investigator to be at imminent risk of suicide or harm to
             self, others, or property. Subject has suicidal ideation at baseline or has attempted
             suicide within 90 days prior to randomization (even without hospitalization).
Clinical trial NCT00510952 (phase 3, status: completed)
Conditions: diabetes mellitus, type 2
ICD codes: E11.65, E11.9, E11.21, E11.36, E11.41, E11.42, E11.44
Drugs: insulin lispro protamine suspension, insulin glargine
SMILES: OC(=O)[C@@H]1CCCN1, [Na+].[Na+].[O-]P([O-])(F)=O
Eligibility criteria:

        Inclusion Criteria:

          -  Have type 2 diabetes mellitus for at least 1 year.

          -  Are greater than or equal to 18 years old.

          -  Have been receiving oral antihyperglycemic medications (OAMs), without insulin, for at
             least 3 months immediately prior to the study and have been on stable doses of at
             least 2 of the following OAMs for the 6 weeks prior to Visit 1: Metformin-
             Sulfonylureas-Dipeptidyl peptidase-IV (DPP-IV) inhibitors-Thiazolidinediones (TZDs)

          -  Have a hemoglobin A1c (HbA1c) greater than or equal to 7.5% and less than or equal to
             10.0%, as measured by a central laboratory before Visit 2.

          -  Body mass index (BMI) greater than or equal to 25 and less than or equal to 45
             kg/meter squared.

        Exclusion Criteria:

          -  Have used insulin therapy (outside of pregnancy) any time in the past 2 years, except
             for short-term treatment of acute conditions, and up to a maximum of 4 weeks.

          -  Have taken any glucose-lowering medications not included in Inclusion Criterion #3;
             (for example, acarbose, miglitol, pramlintide, exenatide, repaglinide, or nateglinide)
             in the past 3 months before Visit 1.

          -  Have had more than 1 episode of severe hypoglycemia, within 6 months prior to entry
             into the study, or is currently diagnosed as having hypoglycemia unawareness.

          -  Have had 2 or more emergency room visits or hospitalizations due to poor glucose
             control in the past 6 months.

          -  Are pregnant or intend to become pregnant during the course of the study or are
             sexually active women of childbearing potential not actively practicing birth control
             by a method determined by the investigator to be medically acceptable.
Clinical trial NCT00371813 (phase 3, status: completed)
Conditions: smoking cessation
ICD codes: Y36.881S, Y36.891S, Y36.880S, Y36.881A, Y36.881D, Y36.890S, Y36.891A
Drugs: varenicline tartrate, placebo
SMILES: [H][C@]12C[C@]([H])(CNC1)C1=CC3=NC=CN=C3C=C21, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Current cigarette smokers between the ages of 18 and 75 years, who are motivated to
             stop smoking

        Exclusion Criteria:

          -  Patients currently suffering from depression, or have been diagnosed with depression
             in the last 12 months, or subjects with past or present history of psychosis, panic
             disorder, or bipolar disorder

          -  Any subject with known severe chronic obstructive pulmonary disease (COPD)
Clinical trial NCT00302770 (phase 3, status: terminated)
Conditions: social anxiety disorder
ICD codes: F20.81, F21, F34.0, F34.1, F42.3, F45.0, F51.5
Drugs: quetiapine
SMILES: OCCOCCN1CCN(CC1)C1=NC2=CC=CC=C2SC2=CC=CC=C12
Reason stopped: 
    this study was terminated due to poor enrollment
  
Eligibility criteria:

        Inclusion Criteria:

          -  Written Confirmed Consent,

          -  All patients meet the DSM IV criteria for generalized social anxiety disorder,

          -  A score ≥ 60 on the LSAS,

          -  male and female aged between 18 and 65 years

        Exclusion Criteria:

          -  Presence of any primary axis I diagnosis other than social anxiety disorder according
             to DSM-IV,

          -  alcohol and/or substance abuse according to DSM-IV criteria within the last 12 months,

          -  any personality disorder as the primary diagnosis, with the exception of avoidant
             personality disorder,

          -  patients at risk of suicide
Clinical trial NCT01181102 (phase 3, status: completed)
Conditions: venous thromboembolism
ICD codes: O88.22, O88.23, O88.211, O88.212, O88.213, O88.219
Drugs: edoxaban, enoxaparin sodium
SMILES: CN(C)C(=O)[C@H]1CC[C@H](NC(=O)C(=O)NC2=NC=C(Cl)C=C2)[C@@H](C1)NC(=O)C1=NC2=C(CN(C)CC2)S1, [H][N]([H])([H])[Pt](Cl)(Cl)[N]([H])([H])[H]
Eligibility criteria:

        Inclusion Criteria:

          -  Patients undergoing unilateral total knee arthroplasty

        Exclusion Criteria:

          -  Subjects with risks of hemorrhage

          -  Subjects with thromboembolic risks

          -  Subjects who weigh less than 40 kg

          -  Subjects who are pregnant or suspect pregnancy, or subjects who want to become
             pregnant.